Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

NHS treatment decision

Showing 12 out of 27 results
3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021

3D visualisation of thyroid cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer. The National Institute for Health and Care Excellence (NICE) has recommended the use of the drug selpercatinib (Retevmo) for some people in England with a type of advanced thyroid cancer.

by Harry Jenkins | News | 1 October 2021

1 October 2021

A microscopy image showing ball of prostate cells expressing a potential new marker (red) for aggressive prostate cancer.

Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option. Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option.

by Cancer Research UK | News | 14 September 2021

14 September 2021

3D rendering of oesophageal cancer

The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer. The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer.

by Harry Jenkins | News | 11 August 2021

11 August 2021

The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy. The National Institute of Health and Care Excellence (NICE) has approved the use of pemigatinib in adults with a rare type of bile duct cancer that has continued to advance or spread after initial chemotherapy.

by Harry Jenkins | News | 22 July 2021

22 July 2021

Bowel cancer cells under a microscope

People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England. People who have previously been treated for a type of bowel cancer that has spread to other parts of their body will now have another treatment option in England.

by Harry Jenkins | News | 16 June 2021

16 June 2021